Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human APOC1 Antibodies:
anti-Rat (Rattus) APOC1 Antibodies:
anti-Mouse (Murine) APOC1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal APOC1 Primary Antibody for ELISA, WB - ABIN559900
Meunier, Russell, Engle, Faulk, Purcell, Emerson: Apolipoprotein c1 association with hepatitis C virus. in Journal of virology 2008
Show all 3 references for ABIN559900
Human Polyclonal APOC1 Primary Antibody for IHC (p) - ABIN375143
Berbée, van der Hoogt, Sundararaman, Havekes, Rensen: Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. in Journal of lipid research 2005
Human Polyclonal APOC1 Primary Antibody for IHC (p), IP - ABIN152922
Sun, Lin, Lee, Wang, Cheng, Wu, Chang, Lai, Shieh, Young: Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. in Gut 2013
apoC-I and apoC-III (show APOC3 Antibodies) inhibit lipolysis by displacing LPL (show LPL Antibodies) from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL (show LPL Antibodies) by factors such as angptl4 (show ANGPTL4 Antibodies).
Common single-nucleotide polymorphism in the APOC1/APOE (show APOE Antibodies) region, previously found to be associated with protective levels of cholesterol and lower cardiovascular risk, may be associated with ideal health.
These findings indicated that variants in TOMM40 (show TOMM40 Antibodies)/APOE (show APOE Antibodies)/APOC1 region might be associated with human longevity. Further studies are needed to identify the causal genetic variants influencing human longevity.
These results suggest that ApoC-I peptides may be a potential diagnostic biomarker and therapeutic approach for breast cancer.
APOC1 SNP is associated with the A beta (show SUCLA2 Antibodies)-42 levels in CSF (show CSF2 Antibodies).
This sbioinformatics analysis explored the shared genetic etiology underlying Type 2 Diabetes and Alzheimer's Disease on SNP level, gene level, and pathway level. Six SNPs on APOC1 gene.
The endogenous retroviral promoters (LTRs) of the human endothelin B receptor (EDNRB (show EDNRB Antibodies)) and apolipoprotein C1 (APOC1) genes have high sequence identity but differ in activity and tissue specificity.
The ability of apoC1 to inhibit CETP (show CETP Antibodies) activity is impaired in patients with diabetes. Glycation of apoC1 leads to a change in its electrostatic properties that might account, at least in part, for a loss of constitutive CETP (show CETP Antibodies) inhibition and an increase in plasma CETP (show CETP Antibodies) activity in patients with diabetes.
APOE (show APOE Antibodies) e4 allele status is associated with dementia and severity of Alzheimer's disease pathologic features in Parkinson disease.
Data indicate that apolipoprotein C-I (APOC1) rs11568822 polymorphism was associated with increased Alzheimer's disease (AD) risk in Caucasians, Asians and Caribbean Hispanics, but not in African Americans.
Helical domains that mediate lipid solubilization and ABCA1 (show ABCA1 Antibodies)-specific cholesterol efflux in apolipoproteins C-I and A-II
Apolipoprotein C-I was significantly increased in obese mice plasma.
The absence of ApoC-I results in impaired memory functions, which is, together with previous data, suggestive of an important, bell-shaped gene-dose dependent role for ApoC-I in appropriate brain functioning
Data show that the stimulating effect of apoCI on the lipopolysaccharide (LPS (show TLR4 Antibodies))response resembles that of LPS-binding protein (LBP (show LBP Antibodies)) and depends on CD14 (show CD14 Antibodies)/ Toll-like receptor 4 (show TLR4 Antibodies) signaling.
present observations provide direct support for a potent specific inhibition of CETP (show CETP Antibodies) by plasma apoCI in vivo
The apoC-I content of lipoprotein remnants may serve as an early marker of coronary artery disease risk.
TR4 (show NR2C2 Antibodies) can also regulate apolipoprotein E (show APOE Antibodies), C-I, and C-II gene expression via the TR4 (show NR2C2 Antibodies) response element within the hepatic control region
apoC-I is a potent inhibitor of LPL (show LPL Antibodies)-mediated triglyceride lipolysis
irrespective of receptor-mediated remnant clearance by the liver, liver-specific expression of recombinant human apoCI causes hypertriglyceridemia in the absence of the VLDLr (show VLDLR Antibodies) and apoCIII (show APOC3 Antibodies) in mice
Endogenous apoC-I increases hyperlipidemia in apoE (show APOE Antibodies)-knockout mice by stimulating VLDL production and inhibiting LPL (show LPL Antibodies).
Systemic apoCI increases atherosclerosis, probably by inducing hyperlipidemia, in the absence of ApoE (show APOE Antibodies)
Cholesteryl ester transfer protein (show CETP Antibodies) is the sole major determinant of cholesteryl ester transfer in normolipidemic rabbit plasma as a result of the inability of rabbit apoCI to change HDL (show HSD11B1 Antibodies) electronegativity.
The protein encoded by this gene is a member of the apolipoprotein C1 family. This gene is expressed primarily in the liver, and it is activated when monocytes differentiate into macrophages. A pseudogene of this gene is located 4 kb downstream in the same orientation, on the same chromosome. This gene is mapped to chromosome 19, where it resides within a apolipoprotein gene cluster. Alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined.
, Apolipoprotein C-I
, apolipoprotein C1
, liver regeneration-related protein LRRG04